H3 K27M Mutations in Thalamic Pilocytic Astrocytomas with Anaplasia.

Anaplasia Chemotherapy H3 K27M mutation Pilocytic astrocytoma Radiation Surgery Thalamic

Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 31 08 2018
revised: 14 12 2018
accepted: 17 12 2018
medline: 15 1 2019
pubmed: 15 1 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

The revised World Health Organization classification of central nervous system tumors, published in 2016, has recognized the H3 K27M mutation as a critical genetic signature defining a new group of infiltrative astrocytomas designated as diffuse midline glioma, H3 K27M mutant. Although most H3 K27M mutations arise in the setting of diffusely infiltrative tumors, there are rare reports of compact tumors with low-grade histologic features harboring this mutation. The prevalence and clinical significance of this mutation in pilocytic astrocytomas remain unclear. We report 2 young adult patients with H3 K27M-mutated thalamic pilocytic astrocytomas who presented to medical attention with symptomatic hydrocephalus requiring urgent intervention. We present our experience with this unusual tumor and recommend a treatment paradigm of maximal safe surgical resection followed by chemotherapy and radiation. Stereotactic biopsies may undergrade some adult thalamic pilocytic astrocytomas. Therefore, we recommend that all these tumors be evaluated for the H3 K27M mutation. Further, we think H3 K27M-mutant thalamic pilocytic astrocytomas require aggressive multimodality treatment and these treatments should be guided by the molecular findings, as opposed to the histologic ones.

Sections du résumé

BACKGROUND BACKGROUND
The revised World Health Organization classification of central nervous system tumors, published in 2016, has recognized the H3 K27M mutation as a critical genetic signature defining a new group of infiltrative astrocytomas designated as diffuse midline glioma, H3 K27M mutant. Although most H3 K27M mutations arise in the setting of diffusely infiltrative tumors, there are rare reports of compact tumors with low-grade histologic features harboring this mutation. The prevalence and clinical significance of this mutation in pilocytic astrocytomas remain unclear.
CASE DESCRIPTION METHODS
We report 2 young adult patients with H3 K27M-mutated thalamic pilocytic astrocytomas who presented to medical attention with symptomatic hydrocephalus requiring urgent intervention. We present our experience with this unusual tumor and recommend a treatment paradigm of maximal safe surgical resection followed by chemotherapy and radiation.
CONCLUSIONS CONCLUSIONS
Stereotactic biopsies may undergrade some adult thalamic pilocytic astrocytomas. Therefore, we recommend that all these tumors be evaluated for the H3 K27M mutation. Further, we think H3 K27M-mutant thalamic pilocytic astrocytomas require aggressive multimodality treatment and these treatments should be guided by the molecular findings, as opposed to the histologic ones.

Identifiants

pubmed: 30639498
pii: S1878-8750(19)30015-4
doi: 10.1016/j.wneu.2018.12.147
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

87-92

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Tarek Y El Ahmadieh (TY)

Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Aaron Plitt (A)

Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Benjamin Kafka (B)

Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Salah G Aoun (SG)

Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Jack M Raisanen (JM)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Brent Orr (B)

Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Edward Pan (E)

Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Zabi Wardak (Z)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Lucien A Nedzi (LA)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Toral R Patel (TR)

Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: toral.patel@utsouthwestern.edu.

Classifications MeSH